Navigation Links
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Date:3/3/2009

actor receptor inhibitors like Erbitux(R) and Tarceva(R). The Company has additional pipeline opportunities that, like Marqibo, improve delivery and enhance the therapeutic index of well characterized, proven chemotherapies. Further information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,'' ``expects,'' ``plans,'' ``believes,'' ``intends,'' and similar words or phrases. These forward-looking statements include without limitation, statements regarding the expected benefits Marqibo may have for patients with relapsed ALL, expected benefits of Marqibo versus standard vincristine, potential dosing regimens, the timing, progress and anticipated results of the clinical development, regulatory processes and rates of patient enrollment of the rALLy trial, and the expected safety profile of Marqibo. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there is no assurance that Hana will have sufficient capital to complete the development of Marqibo, that the safety profile of Marqibo observed to date will be predictive of future results, that the results of the rALLy trial to date will be predictive of future results, that the rALLy trial will meet its study objectives, that Hana's development efforts relating to Marqibo will be successful, that Hana will be able to obtain
'/>"/>

SOURCE Hana Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
2. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
3. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
4. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
5. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
10. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: ... protective equipment for all forms of sports, including extreme ... neck brace, announced today that the UISP Lega Motociclismo ... requires all riders to wear a neck brace during ...
(Date:1/23/2015)... BOSTON , January 23, 2015 ... company, is delighted to announce that the Malcolm Campbell ... Miles Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions ...
(Date:1/22/2015)... UPI ), a medical device company that develops, ... dysfunctions, today reported financial results for the fiscal 2015 ... for the Company,s Urgent ®  PC Neuromodulation System grew ... as compared to $3.9 million in the third quarter ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... postmenopausal women with any risk levels of breast cancer. According ... September 1 issue of Clinical Cancer Research//, Raloxifene could protect ... they are at high or low risk of developing the ... drug could reduce the risk in women with a family ...
... medical trusts facing major losses to outsource medical transcription work ... ,Around 60 specialist posts are to be abolished as ... be facing debts of 84 million pounds. Several other hospitals ... ,The outsourcing plans, however, have been fiercely criticised by ...
... Social Justice and Empowerment, Smt. Meira Kumar will ... Secretaries of States/ UTs, here, tomorrow.// The meeting ... different Disabilities related Schemes being implemented by the ... of creating a barrier free environment in public ...
... is so common among Americans that it almost feels ... that although the underlying cause of persistent fatigue can ... is imaginary.// ,According to Boosting Your Energy, fatigue ... Still, most people—even those being treated for fatigue-producing illnesses—can ...
... The National Institute of Health has said that it will ... cancer to sequence all the genetic changes that lead to ... Cancer Genome Atlas project will pinpoint hundreds or thousands of ... used to develop better drugs to treat it and tools ...
... recent survey by a drug charity has revealed that ... to improve their looks as well as to boost ... traditionally used by body builders and athletes to improve ... young professionals and building site workers between the ages ...
Cached Medicine News:Health News:Raloxifene Reduces The Risk Of Breast Cancer 2Health News:Raloxifene Reduces The Risk Of Breast Cancer 3Health News:Leeds Hospitals to Outsource Medical Transcription Work to India 2Health News:Boosting Energy Naturally 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: